5-benzylacyclouridine manufacturers
|
| | 5-benzylacyclouridine Basic information |
| Product Name: | 5-benzylacyclouridine | | Synonyms: | 5-benzylacyclouridine;5-Benzyl-1-(2-hydroxyethoxymethyl)uracil;2,4(1H,3H)-Pyrimidinedione, 1-[(2-hydroxyethoxy)methyl]-5-(phenylmethyl)-;6-Benzyl-1-(2-hydroxy ethoxymethyl)uracil;Benzylacyclouridine | | CAS: | 82857-69-0 | | MF: | C14H16N2O4 | | MW: | 276.29 | | EINECS: | | | Product Categories: | | | Mol File: | 82857-69-0.mol |  |
| | 5-benzylacyclouridine Chemical Properties |
| Melting point | 144-145 °C(Solv: ethanol (64-17-5)) | | density | 1.290±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : 100 mg/mL (361.94 mM; Need ultrasonic) | | pka | 9.43±0.10(Predicted) | | form | Solid | | color | White to light yellow |
| | 5-benzylacyclouridine Usage And Synthesis |
| Uses | Benzylacyclouridine (BAU) is a potent and specific inhibitor of uridine phosphorylase, the first enzyme in the catabolism of uridine. Benzylacyclouridine can modulate the cytotoxic side effects of 5-fluorouracil (5-FU) and its derivatives[1][2][3]. | | Definition | ChEBI: A pyrimidone that is uracil which is substituted by a 2-hydroxyethoxymethyl group at position 1 and a benzyl group at position 5. | | in vivo | Benzylacyclouridine (p.o. or i.v.) arrests the rapid degradation of a tracer dose of uridine into uracil in dogs and pigs[1].
Benzylacyclouridine exhibits the t1/2 of 1.8-3.6 h in dogs, with bioavailability levels of 85% (30 mg/kg) and 42.5% (120 mg/kg)[1].
Benzylacyclouridine (120 mg/kg) exhibits the t1/2 of 1.6-2.3 h, with a bioavailability of 40% in pigs[1]. | | References | [1] Pizzorno G, et, al. Phase I clinical and pharmacological studies of benzylacyclouridine, a uridine phosphorylase inhibitor. Clin Cancer Res. 1998 May;4(5):1165-75. PMID:9607574
[2] Monks A, et, al. Effect of 5-benzylacyclouridine, a potent inhibitor of uridine phosphorylase, on the metabolism of circulating uridine by the isolated rat liver. Biochem Pharmacol. 1983 Jul 1;32(13):2003-9. DOI:10.1016/0006-2952(83)90419-7
[3] Roosild TP, et, al. Implications of the structure of human uridine phosphorylase 1 on the development of novel inhibitors for improving the therapeutic window of fluoropyrimidine chemotherapy. BMC Struct Biol. 2009 Mar 16;9:14. DOI:10.1186/1472-6807-9-14 |
| | 5-benzylacyclouridine Preparation Products And Raw materials |
|